Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Primary Purpose
Irritable Bowel Syndrome (IBS)
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Fecal transplantation
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome (IBS) focused on measuring Fecal transplantation, microbiota transplantation, irritable bowel syndrome, IBS
Eligibility Criteria
Inclusion criteria for patients
- Signed informed consent
- Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or discomfort for at least 2 days a week in the last 12 weeks
- Age: 18-65 years
Exclusion criteria for patients
- High proportion of butyrate-producing microbiota in fecal samples
- Known organic gastrointestinal disease (e.g. IBD)
- Previous complicated gastrointestinal surgery
- Non-gastrointestinal malignancy
- Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
- Females who are pregnant or breast-feeding
- Severe endometriosis
- Antimicrobial treatment 4 weeks prior to first screening visit
- Antimicrobial prophylaxis (eg. acne, urinary tract infection)
- Regular consumption of probiotic products 4 weeks prior to randomization
- Recently (within the last 3 months) diagnosed lactose intolerance
- Celiac disease
- Abuse of alcohol or drugs
- Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial
Inclusion criteria for donors
- Signed informed consent
- High-butyrate producing microbiota in fecal samples
- Age: 18-65 years
Exclusion criteria for donors
- Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or constipation)
- Gastrointestinal malignancy or polyposis
- History of major gastrointestinal surgery (e.g. gastric bypass)
- Eosinophilic disorders of the gastrointestinal tract
- Current communicable disease (e.g. upper respiratory tract infection)
- Known or high risk of infectious diseases such as HIV, hepatitis A, B or C
- Non-gastrointestinal malignancy
- Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
- Comorbidities such as metabolic syndrome, autoimmune diseases, allergies
- Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia)
- Severe or morbid obesity
- Use of immunosuppressive or chemotherapy agents
- Antimicrobial treatment or prophylaxis within the last 6 months
- Females who are pregnant or breast-feeding
- Known clinically significant abnormal laboratory values
- Participation in high-risk sexual behaviors
- Abuse of alcohol or drugs
- Tattoo or body piercing within the last 6 months
- Travel to areas with endemic diarrhea during the last 3 months
- Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen, cryptosporidium antigen
Sites / Locations
- University Hospital Örebro
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Fecal transplantation of own stool
Fecal transplantation (stool from donor)
Arm Description
Autologous fecal transplantation (own stool)
Allogeneic fecal transplantation (from donor)
Outcomes
Primary Outcome Measures
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)
Secondary Outcome Measures
Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)
Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)
Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)
Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)
Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey
Full Information
NCT ID
NCT02092402
First Posted
March 17, 2014
Last Updated
August 27, 2019
Sponsor
Örebro University, Sweden
1. Study Identification
Unique Protocol Identification Number
NCT02092402
Brief Title
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Official Title
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
June 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Örebro University, Sweden
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the effect of fecal microbiota transplantation (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome (IBS)
Keywords
Fecal transplantation, microbiota transplantation, irritable bowel syndrome, IBS
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fecal transplantation of own stool
Arm Type
Placebo Comparator
Arm Description
Autologous fecal transplantation (own stool)
Arm Title
Fecal transplantation (stool from donor)
Arm Type
Experimental
Arm Description
Allogeneic fecal transplantation (from donor)
Intervention Type
Other
Intervention Name(s)
Fecal transplantation
Primary Outcome Measure Information:
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)
Time Frame
2 months
Title
Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)
Time Frame
2 months
Title
Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)
Time Frame
6 months
Title
Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)
Time Frame
2 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria for patients
Signed informed consent
Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or discomfort for at least 2 days a week in the last 12 weeks
Age: 18-65 years
Exclusion criteria for patients
High proportion of butyrate-producing microbiota in fecal samples
Known organic gastrointestinal disease (e.g. IBD)
Previous complicated gastrointestinal surgery
Non-gastrointestinal malignancy
Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
Females who are pregnant or breast-feeding
Severe endometriosis
Antimicrobial treatment 4 weeks prior to first screening visit
Antimicrobial prophylaxis (eg. acne, urinary tract infection)
Regular consumption of probiotic products 4 weeks prior to randomization
Recently (within the last 3 months) diagnosed lactose intolerance
Celiac disease
Abuse of alcohol or drugs
Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial
Inclusion criteria for donors
Signed informed consent
High-butyrate producing microbiota in fecal samples
Age: 18-65 years
Exclusion criteria for donors
Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or constipation)
Gastrointestinal malignancy or polyposis
History of major gastrointestinal surgery (e.g. gastric bypass)
Eosinophilic disorders of the gastrointestinal tract
Current communicable disease (e.g. upper respiratory tract infection)
Known or high risk of infectious diseases such as HIV, hepatitis A, B or C
Non-gastrointestinal malignancy
Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
Comorbidities such as metabolic syndrome, autoimmune diseases, allergies
Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia)
Severe or morbid obesity
Use of immunosuppressive or chemotherapy agents
Antimicrobial treatment or prophylaxis within the last 6 months
Females who are pregnant or breast-feeding
Known clinically significant abnormal laboratory values
Participation in high-risk sexual behaviors
Abuse of alcohol or drugs
Tattoo or body piercing within the last 6 months
Travel to areas with endemic diarrhea during the last 3 months
Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen, cryptosporidium antigen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Brummer, MD, PhD
Organizational Affiliation
University Hospital Örebro, Department of Gastroenterology and Örebro University, School of Health and Medical Sciences, Faculty of Medicine and Health, Örebro, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Örebro
City
Örebro
ZIP/Postal Code
70185
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
We'll reach out to this number within 24 hrs